Friday, September 27, 2013

Want to know who is Supporting Congress' Agreement on the Drug Quality and Security Act--Read this


WHAT THEY’RE SAYING: DRUG QUALITY AND SECURITY ACT

September 27, 2013
“This compromise legislation addresses the issues that led to the NECC tragedy, protects the physician-patient-pharmacist relationship, maintains critical patient access to compounded medications, and strengthens the pharmaceutical supply chain.” - NCPA
WASHINGTON, DC – Earlier this week, House Energy and Commerce Committee Chairman Fred Upton (R-MI) and Senate HELP Committee Chairman Tom Harkin (D-IA) announced bipartisan, bicameral legislation to address high-risk drug compounding practices and strengthen America’s pharmaceutical supply chain. H.R. 3204 – the Drug Quality and Security Act – builds upon the Energy and Commerce Committee’s extensive efforts to improve drug safety and help prevent a future public health crisis like the 2012 meningitis outbreak tied to the New England Compounding Center.
In addition to the bill’s introduction, momentum continues to build around this important effort as dozens of groups have voiced their support. A sampling of the support is provided below:
“This compromise proposal provides a balanced and effective approach to address critical and complex issues surrounding compounded medications, as well as strengthening our nation’s pharmaceutical supply chain. NCPA applauds the House for moving this legislation in expeditious fashion, and urge members to vote in favor of this bipartisan compromise. … NCPA commends the Congress for crafting bipartisan legislation that addresses the New England Compounding Center (NECC) tragedy, ensures quality standards for all compounded pharmaceuticals, and maintains patient access to vital compounded medications.”
“Cancer patients and providers support a pharmaceutical distribution system that will protect against the counterfeit medicines that have put cancer patients at risk in the recent past. Distribution system protections

another recall


The Compounding Shop: FDA News Release - Lack of Sterility Assurance of Drug Products

By Newsroom America Feeds at 11:00 am EasternUPDATED 09/27/2013. Budesonide solution, used for nasal irrigation, from The Compounding Shop may be contaminated and should not be used or administered to patients. Originally posted 05/08/2013http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMe